Melanoma drug holding up well after further testing
Merck's late-stage melanoma drug, lambrolizumab, continues to show great promise in shrinking the deadly tumors, particularly when taken at the highest dosage offered in trials, according to a study published Thursday in ...
Jul 12, 2013
0
0